Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04636619
Other study ID # 004
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 12, 2021
Est. completion date December 2026

Study information

Verified date February 2024
Source Hospital del Río Hortega
Contact Marina De Benito Sanz, MD
Phone 983420400
Email mbenitosa@saludcastillayleon.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction It has been shown that some quality indicators in endoscopy can be improved through educational interventions. There are marked differences in the proportion of incomplete polypectomies among endoscopists. The effectiveness of measures to improve it has not been evaluated. Objective The main objective is to evaluate whether a training intervention or the notification of the individual proportion of incomplete polypectomies (those in which post-polypectomy biopsies of the resection margin show tissue other than normal mucosa) can improve this proportion. As secondary objectives, we will compare the proportion of fragmented polypectomies and adverse events. We will evaluate the factors associated with incomplete excision or failed cold polypectomy, as well as the individual evolution of the participants. Methods Non-pharmacological clinical trial involving endoscopists with> 1 year of experience and patients scheduled for colonoscopy. After each polypectomy, 2 additional biopsies will be taken and evaluated centrally by a blind pathologist. In a first phase, the basal rate of the participants will be evaluated. After it, the endoscopists will receive a course on endoscopic polypectomy and the other their rate of complete resection. The number of polyps required will vary depending on the number of endoscopists The primary objective will be compared using logistic regression models based on generalized estimating equations (GEE), taking into account the within-subject correlation.


Description:

Design Non-pharmacological clinical trial Methods Study population The population of endoscopists under study includes specialists in the digestive system with more than one year of experience in endoscopies. Candidate patients to be included will be those scheduled to perform a colonoscopy on a non-urgent basis. The patient will be invited to participate prior to the performance of the colonoscopy. Stages of the study Stage I: estimation of incomplete polypectomies All participating endoscopists will include polyps in order to perform the baseline estimate. To avoid that the estimation is made on the basis of a small group of participants, a minimum number of lesions will be required and a maximum threshold for polyps will be established. These thresholds will be estimated as follows: Minimum: sample size / (number of participating endoscopistsx1.5). It can never be less than 25 injuries. Maximum: sample size / (number of participating endoscopists / 1.5) Once there are a sufficient number of endoscopists who are at the thresholds allowing their samples to reach the established sample size, the end of patient recruitment will be set for the baseline estimate 30 days later. After this period, all endoscopists who do not reach the minimum threshold will be excluded from the study. Stage II: Online training course An online course will be offered that will explain the technique for excision of lesions with a cold loop and the importance of complete resection, techniques to determine the edges of the lesion and possible remains at the polypectomy base through images, video clips. and interaction with the speakers. After the training measures, each endoscopist will proceed to recruit a minimum number of polyps that will be determined based on the sample size reached in phase I. Once the pre-established sample size has been reached, this phase will be closed. E) Recruitment, procedure and follow-up Patient recruitment is the same in all phases. Patients who meet the inclusion criteria and do not present any exclusion criteria (pre-endoscopic) will be invited to participate in the study. Informed consent will be completed in accordance with law 41/2002 on patient autonomy without thereby altering the relationship with their doctor or causing any harm to their treatment. Anonymized video clips of all polypectomies will be recorded in each of the phases, including from when the polypectomy loop is inserted into the endoscope until the biopsies are taken from the base of the polyp. 1. Endoscopic act The interventions will be carried out in each of the participating centers. The examinations will be carried out under sedation, following the protocols established in each center. Once the lesion is identified, it will be removed using a cold loop. This will be carried out following the usual standards recommended by international companies. If macroscopic remains of the lesion are observed, a fragmented polypectomy should be performed using, in the same way, the cold loop. Once the polypectomies are completed, its base will be carefully evaluated, taking biopsies 2 random biopsies at the base of the polypectomy, at two of the ends of the eschar. 2. Post-endoscopic follow-up In the 5th week post-colonoscopy from the endoscopic examination, the patient will be contacted by telephone to collect possible complications (they will be questioned about visits to the hospital and in a directed way about the most frequent symptoms of the usual complications (fever, bleeding, abdominal pain ), and if so, the medical history will be reviewed to assess the severity of the complication. 3. Histological analysis The analysis of the polypectomy specimens will be carried out in each center according to its usual protocol. The analysis of the biopsies of the base of the polyp will be performed centrally by a pathologist with more than 5 years of experience in digestive pathology. Samples from the base of the polyp will be sent from each center for centralized study. The pathologist will be blinded as to the histological diagnosis of the removed polyp. Samples submitted for centralized analysis will not be kept, but will be destroyed once the study is completed according to standard protocols 1) Endoscopic act The interventions will be carried out in each of the participating centers. The examinations will be carried out under sedation, following the protocols established in each center. Once the lesion is identified, it will be removed using a cold loop. This will be carried out following the usual standards recommended by international companies. If macroscopic remains of the lesion are observed, a fragmented polypectomy should be performed using, in the same way, the cold loop. Once the polypectomies are completed, its base will be carefully evaluated, taking biopsies 2 random biopsies at the base of the polypectomy, at two of the ends of the mucosal defect. F) Sample size According to the results obtained in our previous work, we observed an intra-subject correlation coefficient (taking the endoscopists as subjects) of 0.017. The sample size will depend on the number of participating endoscopists. Assuming a baseline proportion of incomplete polypectomies of 7.5%, to detect an absolute risk reduction of 3.5% (that is, to identify as different proportions equal to or less than 4%) with an alpha risk of 5% and a 80% power, the required number of polyps will vary depending on the group of participating endoscopists. According to our previous work, a 2.5% loss should also be assumed. Given that to estimate the proportion of incomplete polypectomies with a margin of error of +/- 1.5% for any value below 3.5%, a maximum of 558 polyps would be needed, in case of presenting a baseline proportion of incomplete polypectomies < 4%, we could estimate the confidence intervals accurately. G) Data collection All the variables concerning the characteristics of the endoscopist, the patient and the injuries included will be collected in each center. The variables related to the histological diagnosis of the polypectomy specimen will be collected in the same way at the respective center. The variables concerning the follow-up will be collected centrally, through a telephone call that will be made the 5th week after the procedure. The variable related to the histological study of the base of the polyp will be collected centrally by the pathologist in charge of analyzing the samples. The video clips will be stored in a collection created de novo and centralized in the main researcher center 2) Post-endoscopic follow-up In the 5th week post-colonoscopy from the endoscopic examination, the patient will be contacted by telephone to collect possible complications (they will be questioned about visits to the hospital and in a directed way about the most frequent symptoms of the usual complications (fever, bleeding, abdominal pain ), and if so, the medical history will be reviewed to assess the severity of the complication. 3) Histological analysis The analysis of the polypectomy specimens will be carried out in each center according to its usual protocol. The analysis of the biopsies of the base of the polyp will be performed centrally by a pathologist with more than 5 years of experience in digestive pathology. Samples from the base of the polyp will be sent from each center for centralized study. The pathologist will be blinded as to the histological diagnosis of the removed polyp. Samples submitted for centralized analysis will not be kept, but will be destroyed once the study is completed according to standard protocols. Data collection The data from the data collection notebooks will be collected anonymously by the main investigator or collaborating investigators, encrypted and dissociated from the clinical information by means of a patient identification code (ID), in a database created by the program Research Electronic Data Capture Tool (RedCap) (17) attached to the Spanish Society of Digestive Endoscopy, which allows coordinating data collection through access from different national centers. Subsequently, for their analysis, they will be merged by the principal investigator or the encrypted and dissociated collaborating investigators, in a database created using the STATA Stata Corporation program. 2013. Stata Statistical Software: Release 13. College Station, Texas: Stata Corporation. The data entered in the database will be encrypted and the database will be protected with a password to which only researchers will have access. The video clips will be completely anonymized and identified by a code, which will be provided by the main researcher. In no case will identifying data of the patient appear in said videos. The unified file will be kept at the Río Hortega University Hospital and will be kept until the end of the study. Regarding the application of the Organic Law on Data Protection 15/1999 and the Royal Decree 1720/2007 that develops it, it should be noted that the protocol defined in the project aimed at epidemiological analysis determines that the files will record information completely anonymized. Statistical analysis In the quantitative variables, the arithmetic mean and standard deviation will be calculated (the variables that do not follow a normal distribution according to the Kolmogorov-Smirnov test will be described with median and interquartile range), and the qualitative ones will be expressed as percentages and their intervals of 95% confidence. The main objective, the difference in the proportion of indicators collected in the reports made with free fields or with standardized reports, will be compared using logistic regression models based on generalized estimating equations (GEE), taking into account the within-subject correlation. . Among the secondary endpoints, the proportion of complications in both groups, the proportion of fragmented polypectomies and polypectomies that require repositioning will be compared using the homogeneity z-test without using the Yates correction. Multivariate logistic regression techniques will be used to evaluate the factors associated with incomplete polypectomies and those associated with a failed cold polypectomy. The individual evolution of the endoscopists will be displayed graphically. Cumulative summatory learning curves will be used to graphically represent the individual evolution of the endoscopists.


Recruitment information / eligibility

Status Recruiting
Enrollment 1920
Est. completion date December 2026
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients over 18 years of age scheduled for a non-urgent colonoscopy. Exclusion Criteria: - Absence of lesions <10 mm. - Contraindication for polypectomy (anticoagulant treatment that cannot be withdrawn, treatment with clopidogrel, coagulopathy or severe thrombocytopenia) - Loss of polypectomy specimen - Refusal to participate

Study Design


Intervention

Procedure:
Colonic polypectomy
Cold snare resection of colorectal polyps
Behavioral:
Online training course
Polypectomy technique online course

Locations

Country Name City State
Spain Hospital Rio Hortega Valladolid

Sponsors (1)

Lead Sponsor Collaborator
Hospital del Río Hortega

Country where clinical trial is conducted

Spain, 

References & Publications (14)

Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009 Jan 6;150(1):1-8. doi: 10.7326/0003-4819-150-1-200901060-00306. Epub 2008 Dec 15. — View Citation

Baxter NN, Warren JL, Barrett MJ, Stukel TA, Doria-Rose VP. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol. 2012 Jul 20;30(21):2664-9. doi: 10.1200/JCO.2011.40.4772. Epub 2012 Jun 11. — View Citation

Bourke MJ. Making every colonoscopy count: Ensuring quality in endoscopy. J Gastroenterol Hepatol. 2009 Oct;24 Suppl 3:S43-50. doi: 10.1111/j.1440-1746.2009.06070.x. — View Citation

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313. — View Citation

Coe SG, Crook JE, Diehl NN, Wallace MB. An endoscopic quality improvement program improves detection of colorectal adenomas. Am J Gastroenterol. 2013 Feb;108(2):219-26; quiz 227. doi: 10.1038/ajg.2012.417. Epub 2013 Jan 8. — View Citation

Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027. No abstract available. — View Citation

Grupo de Trabajo de "Indicadores de calidad en endoscopia" de la Sociedad Espanola de Patologia Digestiva (SEPD). Quality indicators in colonoscopy. The colonoscopy procedure. Rev Esp Enferm Dig. 2018 May;110(5):316-326. doi: 10.17235/reed.2018.5408/2017. — View Citation

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. — View Citation

Mulder SA, van Soest EM, Dieleman JP, van Rossum LG, Ouwendijk RJ, van Leerdam ME, Kuipers EJ. Exposure to colorectal examinations before a colorectal cancer diagnosis: a case-control study. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):437-43. doi: 10.1097/MEG.0b013e328333fc6a. — View Citation

Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013 Sep 19;369(12):1095-105. doi: 10.1056/NEJMoa1301969. — View Citation

Pohl H, Srivastava A, Bensen SP, Anderson P, Rothstein RI, Gordon SR, Levy LC, Toor A, Mackenzie TA, Rosch T, Robertson DJ. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013 Jan;144(1):74-80.e1. doi: 10.1053/j.gastro.2012.09.043. Epub 2012 Sep 25. Erratum In: Gastroenterology. 2021 Oct;161(4):1347. — View Citation

Ransohoff DF. Colon cancer screening in 2005: status and challenges. Gastroenterology. 2005 May;128(6):1685-95. doi: 10.1053/j.gastro.2005.04.005. No abstract available. — View Citation

Singh H, Nugent Z, Demers AA, Kliewer EV, Mahmud SM, Bernstein CN. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology. 2010 Oct;139(4):1128-37. doi: 10.1053/j.gastro.2010.06.052. Epub 2010 Jun 20. — View Citation

Ussui V, Coe S, Rizk C, Crook JE, Diehl NN, Wallace MB. Stability of increased adenoma detection at colonoscopy. Follow-up of an endoscopic quality improvement program-EQUIP-II. Am J Gastroenterol. 2015 Apr;110(4):489-96. doi: 10.1038/ajg.2014.314. Epub 2014 Sep 30. — View Citation

* Note: There are 14 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Incomplete resection rate To compare the change in the proportion of incomplete cold-snare polypectomies in polyps <10mm. One year
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A